BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37344639)

  • 1. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
    Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
    Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
    Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
    J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
    Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
    J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
    Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
    Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
    Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
    J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK Inhibition in a Newborn with
    Mussa A; Carli D; Giorgio E; Villar AM; Cardaropoli S; Carbonara C; Campagnoli MF; Galletto P; Palumbo M; Olivieri S; Isella C; Andelfinger G; Tartaglia M; Botta G; Brusco A; Medico E; Ferrero GB
    Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
    Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
    Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAF1 mutation leading to hypertrophic cardiomyopathy in a Chinese family with a history of sudden cardiac death: A diagnostic insight into Noonan syndrome.
    Zheng J; Peng L; Cheng R; Li Z; Xie J; Huang E; Cheng J; Zhao Q
    Mol Genet Genomic Med; 2024 Jan; 12(1):e2290. PubMed ID: 37787490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
    Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
    Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NGS testing for cardiomyopathy: Utility of adding RASopathy-associated genes.
    Ceyhan-Birsoy O; Miatkowski MM; Hynes E; Funke BH; Mason-Suares H
    Hum Mutat; 2018 Jul; 39(7):954-958. PubMed ID: 29696744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
    Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
    Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
    Pelc M; Ciara E; Jezela-Stanek A; Krajewska-Walasek M
    Genet Couns; 2016; 27(3):325-333. PubMed ID: 30204961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome.
    Yin JC; Platt MJ; Tian X; Wu X; Backx PH; Simpson JA; Araki T; Neel BG
    Nat Commun; 2017 May; 8():15518. PubMed ID: 28548091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Raf1 a nexus for cardiac hypertrophic signaling in human disease?
    Del Re DP; Sadoshima J
    J Mol Cell Cardiol; 2011 Jul; 51(1):1-3. PubMed ID: 21539844
    [No Abstract]   [Full Text] [Related]  

  • 16. RAF1 variants causing biventricular hypertrophic cardiomyopathy in two preterm infants: further phenotypic delineation and review of literature.
    Thompson D; Patrick-Esteve J; Surcouf JW; Rivera D; Castellanos B; Desai P; Lilje C; Lacassie Y; Marble M; Zambrano R
    Clin Dysmorphol; 2017 Oct; 26(4):195-199. PubMed ID: 28777121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation.
    Hopper RK; Feinstein JA; Manning MA; Benitz W; Hudgins L
    Am J Med Genet A; 2015 Apr; 167A(4):882-5. PubMed ID: 25706034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
    Uludağ Alkaya D; Lissewski C; Yeşil G; Zenker M; Tüysüz B
    Am J Med Genet A; 2021 Dec; 185(12):3623-3633. PubMed ID: 34184824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical, severe hypertrophic cardiomyopathy in a newborn presenting Noonan syndrome harboring a recurrent heterozygous MRAS variant.
    Pires LVL; Bordim RA; Maciel MBR; Tanaka ACS; Yamamoto GL; Honjo RS; Kim CA; Bertola DR
    Am J Med Genet A; 2021 Oct; 185(10):3099-3103. PubMed ID: 34080768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
    Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
    Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.